Prognostic predictions in B-cell chronic lymphocytic leukemia (B-CLL) at early clinical stage are based on biological disease parameters, such as ZAP-70 and CD38 protein levels, genomic aberrations as well as immunoglobulin variable heavy chain gene (IgV H ) mutation status. In the current study, ZAP-70 and CD38 expressions were examined by flow cytometry in 252 patients with B-CLL. Cytoplasmic ZAP-70 expression in more than 20% (ZAP-70 þ ) and surface CD38 expression on more than 30% (CD38 þ ) of B-CLL cells were associated with an unfavorable clinical course. The levels of ZAP-70 and CD38 did not change over time in the majority of patients where sequential samples were available for analysis. Combined analysis of ZAP-70 and CD38 yielded discordant results in 73 patients (29.0%), whereas 120 patients (47.6%) were concordantly negative and 59 patients (23.4%) were concordantly positive for ZAP-70 and CD38 expression. Median treatment-free survival times in patients whose leukemic cells were ZAP-70 þ CD38 þ was 30 months as compared to 130 months in patients with a ZAP-70
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogeneous disorder characterized by a variable clinical course. 1 Some patients have an aggressive disease requiring early therapy, whereas other patients exhibit a more stable, indolent disease with no benefit from palliative chemotherapy. 2 In a continual effort to identify patients with poor prognosis and to facilitate the clinical management of B-CLL, several prognostic markers have been identified during the last two decades. 3 At first, Rai et al 4 and Binet et al 5 developed clinical staging systems based on leukemia cell burden. These systems have delineated the clinical presentation and natural history of B-CLL and have allowed predicting survival and treatment requirements. However, the Rai and Binet staging systems lack the ability to distinguish prospectively patients with early stage B-CLL that will rapidly progress to aggressive disease from patients destined to remain in early stage for a long time. 1 Therefore, other parameters related to the genetics and biology of B-CLL, such as genomic aberrations and immunoglobulin variable heavy chain (IgV H ) mutation status, are increasingly used for prediction of disease prognosis. 3 In landmark studies, Hamblin et al 6 and Damle et al 7 have shown that survival probability in B-CLL is associated with the absence or presence of somatic mutations in rearranged IgV H genes. Currently, IgV H gene mutation status is considered as one of the most powerful prognostic factors, where B-CLL cases with unmutated IgV H genes are characterized by an unfavorable clinical outcome. 1, 3 However, IgV H mutation analysis is based on DNA sequencing, which is technically demanding and not widely available for routine clinical use. Thus, easily determined surrogate markers for IgV H mutations are required.
DNA microarray studies have shown that B-CLL cells with unmutated IgV H genes can be distinguished from those with mutated IgV H genes by the differential expression of a small number of genes, one of which encodes the 70-kDa zetaassociated protein (ZAP-70). 8, 9 ZAP-70, a member of the Syk-ZAP-70 protein tyrosine kinase family, is a key signaling molecule for T lymphocytes and natural killer cells. While ZAP-70 is not expressed in normal B lymphocytes, it is associated with increased intracellular signaling via the immunoglobulin receptor in B-CLL cells. 10, 11 Considering three recently published studies, [12] [13] [14] ZAP-70 is the most promising surrogate marker for the IgV H mutation status. In contrast to the technically demanding IgV H analysis, ZAP-70 protein expression is conveniently measured by flow cytometry. 12, 15, 16 Initially, CD38 expression also has been suggested as a surrogate marker for the two important IgV H mutated and unmutated subgroups of B-CLL. 7 However, while a plethora of subsequent studies could clearly demonstrate the clinical value of CD38 as a prognostic marker with some degree of correlation to IgV H mutation status, 3 at present, both parameters are regarded as independent prognostic variables in B-CLL. 12, 17 CD38 is a type II transmembrane glycoprotein that acts as a complex ecto-enzyme and receptor molecule with signaling functions in B-CLL cells. 18 Detection of CD38 cell surface expression can be conveniently performed by flow cytometry, and, together with ZAP-70, 14 CD38 analysis may prove a valuable adjunct in the diagnostic work-up of B-CLL patients.
In this study, ZAP-70 and CD38 expressions in relation to clinical information and laboratory parameters including other known prognostic markers were examined in a large series of B-CLL patients. In particular, we aimed to investigate whether CD38 can further refine the clinical relevance of ZAP-70 as an adverse prognostic factor.
Patients, materials and methods

Patients
Between July 2003 and August 2004, 252 patients with B-CLL from two institutions (Department of Hematology and Oncology, University of Goettingen, and Department of Hematology, University of Essen) were enrolled in this retrospective study and analyzed with regard to several biological and clinical characteristics. In accordance with institutional guidelines, heparinized peripheral blood samples were obtained at diagnosis and during routine follow-up visits to our institutions with informed consent. Comprehensive clinical information including treatment histories was available for all patients. Standard clinical criteria were used for the initiation of chemotherapy. 19 
ZAP-70 and CD38 expression
Cytoplasmic ZAP-70 expression was determined by flow cytometry as recently described. 15, 16 Permeabilized cells were analyzed with the anti-ZAP-70 antibody clone 2F3.2 (Upstate Biotechnology, Waltham, MA, USA), CD3-phycoerythrin (PE), CD56-PE (BD Biosciences) and CD19-peridinin chlorophyll protein cytochrome 5.5 (Dako). After appropriate lymphocyte gating, cytoplasmic ZAP-70 expression was determined in CD19 þ B-CLL cells. Cell surface expression of CD38 was examined by flow cytometry using a previously described panel of fluorochrome-labeled monoclonal antibodies (CD38 PE, clone HB7) in a standard three-color flow cytometry approach. 20 IgV H gene analysis Genomic DNA was isolated from cryopreserved cells using the QIAamp blood mini kit (Qiagen, Hilden, Germany). Amplification of the VDJ rearrangements was performed by polymerase chain reaction (PCR) using (5 0 -V H ) framework region (FR) 1 and (3 0 -J H ) Biomed JH family-specific consensus oligonucleotide primers as recently published. 16, 21, 22 The VDJ nucleotide sequences determined were aligned with those in the IgBlast database at the National Center for Biotechnology Information.
Detection of genomic aberrations by fluorescence in situ hybridization
In order to detect prognostically relevant anomalies of chromosomal regions 11q, 13q and 17p and of chromosome 12, the following fluorescent-labeled DNA probes were used in interphase cytogenetic analyses: LSI ATM (11q23), LSI D13S319 (13q14), LSI p53 (17p13.1) and cep12 (centromere 12; all probes purchased from Abbot Vysis, Stuttgart, Germany). Sample preparation, fluorescence in situ hybridization (FISH) and counterstaining with 4,6-diamidino-2-phenylindole dihydrochloride were performed as previously reported. 16 
Oligonucleotide microarray analysis
To further investigate the molecular phenotype of the three clinical subgroups defined by combined determination of ZAP-70 and CD38, we compared their gene expression profiles using HuGeneFL Affymetrix oligonucleotide microarrays representative of approximately 5600 genes. Comparative analysis of gene expression profiles was performed in a subset of 35 patients (10 patients discordant for CD38 and ZAP-70, 16 ZAP-70 À CD38
À patients and nine ZAP-70 þ CD38 þ patients), where gene expression data were available from a previously published study. 23 Only genes recognized as present by the Affymetrix algorithm in at least 29% of either of the three subgroups (n ¼ 3780) were selected for subsequent statistical analysis. For multiclass supervised analysis, we utilized the significance analysis of microarrays (SAM) method, 24 which uses a modified T-test with sample-label permutations to evaluate statistical significance.
Statistical analysis
The primary end point was treatment-free survival from the time of diagnosis. All statistical analyses were performed using the SPSS for Windows. Survival time distributions were plotted using Kaplan-Meier estimates and were compared using the logrank test. The proportional hazards regression model of Cox was used to identify differences in survival time distribution from prognostic factors. As possible prognostic factors, white blood cell counts, platelets, hemoglobin levels, clinical stage (early, Binet A, vs advanced, Binet B and C), serum LDH, b2-microglobulin and thymidine kinase levels, CD38 expression (30% or more vs less than 30%) and ZAP-70 expression (20% or more vs less than 20%) were included in the regression model. The type 1 error rate was set at 5%. Group-wise comparisons of distributions of clinical and biological data were performed with the Mann-Whitney U-test for metric data, Fisher's exact test and the w 2 test for categorical variables. All tests were two-sided. An effect was considered statistically significant at Po0.05.
Results
We studied 252 patients with B-CLL. There were 163 men (65%) and 89 women (35%). At the time of diagnosis, patient ages ranged from 26 to 98 years (median, 61 years); 172 patients (68%) were at Binet stage A, 64 patients (26%) were at Binet stage B and 16 patients (6%) were at Binet stage C. A total of 12 patients had died of causes related to B-CLL at the time of analysis.
ZAP-70 expression
In order to quantify the cytoplasmic expression of ZAP-70 in B-CLL cells, the previously published flow cytometry assay was used. 12 Figure I) .
Evaluation of several disease characteristics in association with the ZAP-70 status of the patients' B-CLL cells showed significant differences for disease stage at diagnosis, disease stage during study, LDH, thymidine kinase and b2-microglobulin À patients had been treated for B-CLL (Fisher's exact test, Po0.001). Significant differences in disease progression as indicated by the treatment-free survival were observed (log-rank test, Po0.001; Figure 1a ). The median treatment-free period was shorter in ZAP-70 þ patients (34 months) as compared to ZAP-70 À patients (130 months). To date, only sparse data regarding the stability of ZAP-70 expression during the disease course have been published. In this study, sequential samples from 38 patients (range 2-4 samples per patient) over time periods ranging from 1 to 34 months were analyzed to investigate whether ZAP-70 expression remains constant over time. In 25 out of 38 cases (65.8%), including 12 treated and 13 untreated patients, ZAP-70 expression differences of p10% were detected. Although 13 cases (34.2%) showed a variation of greater than 10%, only in three (7.9%) of these patients did the change of ZAP-70 expression cross the 20% cutoff (Supplementary Figure II) .
CD38 expression
CD38 surface expression was analyzed utilizing the previously described flow cytometry approach with directly conjugated antibodies. 20 The B-CLL cells were considered CD38-positive when X30% expressed the membrane antigen. 7, 17 Based on this cutoff value, 73 patients (29%) were CD38-positive and 179 patients (71%) were CD38-negative (Supplementary Figure III) .
Comparing the clinical and laboratory parameters of CD38 þ and CD38 À patients, significant differences were found for disease stage at diagnosis, disease stage during study, LDH and b2-microglobulin (Supplementary Table II) . At the time of analysis, 63 (35.2%) of all CD38
À patients and 58 (67.1%) of the CD38 þ patients had received at least one chemotherapeutic regimen. Thus, the treatment histories among the two subgroups differed significantly in that relatively more CD38 þ than CD38
À patients required therapy for B-CLL (Fisher's exact test, Po0.001). In addition, significant differences in disease progression as indicated by the treatment-free time from diagnosis were observed (log-rank test, Po0.001; Figure 1b ). The median treatment-free survival was shorter in CD38 þ patients (31 months) as compared to CD38 À patients (100 months).
Considering the possibility that CD38 expression may be unstable during disease, we further analyzed sequential samples from 60 patients (range 2-9 samples per patient) over periods ranging from 1 to 41 months. In 54 out of 60 cases (90%), including 24 treated and 30 untreated patients, ignorable differences (p10% 7 ) were detected. A total of six (10%) cases showed a variation of greater than 10%. However, only in one patient (1.7%), the utilized 30% cutoff for expression of the CD38 antigen was crossed (Supplementary Figure IV) .
Relation of ZAP-70 and CD38 expression
Next, the relation of ZAP-70 and CD38 protein expression was analyzed in detail. Using the cutoff values of 20% for ZAP-70 and of 30% for CD38 expression, 120 of 252 patients (47.6%) were concordant ZAP-70 À CD38 À and 59 patients (23.4%) were concordant ZAP-70 þ CD38 þ ( Figure 2 ). Although this indicates a highly significant association between these two prognostic factors (Fisher's exact test, Po0.001), for 73 patients (29.0%), there were important discordances. As depicted in Figure 2 , significant levels of ZAP-70 protein without CD38 expression (ZAP-70 þ CD38 À ) were detected in 59 patients (23.4%). On the contrary, 14 patients (5.6%) were found to be CD38-positive but ZAP-70-negative (ZAP-70 À CD38 þ ). The clinical and laboratory data in the subgroups with concordant ZAP-70 Table 1 . Significant differences for disease stages, associated autoimmune disease and serum levels of LDH, thymidine kinase and b2-microglobulin were observed among concordant ZAP-70 þ (n ¼ 118) B-CLL subgroups, respectively (log-rank test, Po0.001 (a)). In CD38 À patients (n ¼ 179), the median survival time without chemotherapy was 100 months, as compared to only 31 months in CD38 þ (n ¼ 73) patients (log-rank test, Po0.001 (b)). (Table 1) ; however, distributions of all parameters were comparable in the two discordant subgroups (Supplementary  Table III þ CD38 þ patients had been treated with chemotherapy for B-CLL. In summary, the treatment histories among these three subgroups differed significantly (w 2 test, Po0.001). Furthermore, significant differences in disease progression as indicated by the treatment-free time from diagnosis were observed between concordant and discordant subgroups (log-rank test, Po0.001; Figure 3a ). The median treatment-free survival was 130 months in concordant ZAP-70 À CD38 À patients, was shorter (43 months) in all discordant patients and was shortest (30 months) in patients of the concordant ZAP-70 þ CD38 þ subgroup. Strikingly, no major differences in survival without therapy were observed between patients with discordant ZAP-70 þ CD38 À and discordant ZAP-70 À CD38 þ status (log-rank test, P ¼ 0.5; Figure 3b ). In the described cohort, the B-CLL diagnosis was made in the majority of patients at Binet stage A disease (n ¼ 172, 68.3%). Prognostic markers should be able to identify those patients in early clinical disease stage who will progress to a more advanced disease requiring early therapy. Accordingly, Kaplan-Meier curves of treatment-free survival were plotted for patients diagnosed with Binet stage A disease (Figure 4 ). Statistical comparisons of the curves revealed significant differences (log-rank test, Po0.001) and the median survival times from diagnosis to first treatment were 38 months for the concordant ZAP-70 þ CD38 þ subgroup, 82 months for the discordant ZAP-70 þ CD38 À or ZAP-70 À CD38 þ subgroup, and median survival time was not reached for ZAP-70 À CD38 À patients. Using Cox proportional hazards regression analysis, we compared ZAP-70 and CD38 expression with other prognostic factors, namely white blood cell and platelet count, hemoglobin level, early and advanced clinical stage and serum concentrations of LDH, thymidine kinase and b2-microglobulin. Platelet count, LDH and b2-microglobulin concentration, clinical stage, ZAP-70 expression and CD38 expression had an impact on treatment-free survival in univariate analyses, and subsequently, were included in the multivariate Cox regression analysis. Only ZAP-70 expression in at least 20% of the cells (Po0.001), CD38 expression on X30% CLL cells (P ¼ 0.008), Binet stage B or C at diagnosis (Po0.001) and increased b2-microglobulin serum level (P ¼ 0.01) had independent power predicting an unfavorable prognosis. The probability value for interactions between CD38 and ZAP-70 was 0.3. The P-value is for comparison among the three subgroups, and was calculated using the Kruskal-Wallis test. ITP, immune thrombocytopenia; AIHA, autoimmune hemolytic anemia. Relation between CD38 and ZAP-70 expression in 252 B-CLL patients. The proportion of CD38 þ B-CLL cells is shown on the x-axis; ZAP-70 positivity in percent of B-CLL cells is shown on the yaxis. The indicated cutoff values are 30% for CD38 expression and 20% for ZAP-70 expression. There is a strong association between both predictive markers in the majority (71%, n ¼ 179) of patients (Fisher's exact test, Po0.001). However, in 29% (n ¼ 73) of the described B-CLL cases, discordant results for expression of CD38 and ZAP-70 are observed.
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IgV H mutation status in ZAP-70/CD38 discordant B-CLL
In the majority of the described CD38 and ZAP-70 discordant patients, high-level expression of cytoplasmic ZAP-70 without significant cell surface levels of CD38 antigen was observed (ZAP-70 þ CD38 À ; Figure 5 ). Considering the previously shown association between ZAP-70 and IgV H mutational status, [12] [13] [14] we asked whether ZAP-70 expression was also a surrogate for 
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À subgroup (n ¼ 120), the median survival time without chemotherapy was 130 months; in the discordant patients (ZAP-70 þ CD38 À or ZAP-70 À CD38 þ ; n ¼ 73), median survival time was 43 months; and in the ZAP-70 þ CD38 þ subgroup (n ¼ 59), patients' median treatment-free survival was 30 months (log-rank test, Po0.001 (a)). No major differences in treatment-free survival as depicted in Kaplan-Meier plots were observed among discordant ZAP-70 þ CD38 À (n ¼ 59) and discordant ZAP-70 
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À patients (n ¼ 101), the median survival time without chemotherapy was not reached; in discordant patients (ZAP-70 þ CD38 À or ZAP-70 IgV H mutation status in B-CLL patients discordant for ZAP-70 and CD38 expression. The IgV H mutation status is indicated as percentage of homology to germline sequences on the y-axis. 6, 14 were identified, despite the fact that our patients were selected for ZAP-70/CD38 discordance. Utilizing an IgV H homology cutoff value of 98%, 17 we found somatic hypermutations in 18 (39.1%) and unmutated IgV H sequences in 28 (60.9%) of our ZAP-70/CD38 discordant patients. As shown in Figure 5, 
Relation of genomic aberrations and expression of ZAP-70 and CD38
Clonal genomic aberrations, such as deletions of chromosomes 17p, 11q and 13q, are important prognostic factors in B-CLL and can be identified in approximately 80% of patients. 25 To evaluate the relation of genomic aberrations and combined ZAP-70/CD38 immunophenotypes in the described B-CLL cohort, interphase cytogenetic analyses by FISH To further investigate the molecular phenotype of the three clinical subgroups defined by combined determination of ZAP-70 and CD38, multiclass supervised analysis of gene expression profiles was performed using the SAM method. Employing a false discovery rate of q ¼ 11.76%, we identified 37 genes ( Figure 7 ) that were differentially expressed among the three subgroups, that is, four out of these 37 genes may be falsely classified as statistically significant. Figure 7 shows that the most prominent gene expression differences were found for the comparison of ZAP-70 þ CD38 þ vs ZAP-70 À CD38 À cases, whereas samples with a discordant ZAP-70/CD38 expression status usually exhibited intermediate signal intensities. Notably, the majority of differentially expressed genes showed a relative upregulation in the ZAP-70 þ CD38 þ as compared to the ZAP-70 À CD38 À and ZAP-70/CD38 discordant subgroups.
Discussion
Expressions of ZAP-70 and CD38, as determined by flow cytometry, have previously been identified by several groups as predictors of disease progression and overall survival in B-CLL (for review, see Shanafelt et al 3 ). In the current study, we aimed to (i) confirm our own previous results concerning the prognostic value of ZAP-70 15 and CD38 20, 23 in a large cohort of 252 patients with B-CLL, and to (ii) investigate whether combined analysis of ZAP-70 and CD38 improves the predictive power of either of the two factors.
Utilizing a previously established flow cytometry assay, 12, 15 we found that B-CLL cases with a high percentage of ZAP-70-positive (X20%) leukemic cells are characterized by an unfavorable clinical course and a significantly reduced treatment-free survival as compared to ZAP-70-negative (o20%) patients. These results are in accordance with the pioneering Genomic abnormalities in B-CLL patients according to combined ZAP-70 and CD38 expression. Chromosomal aberrations were analyzed by interphase FISH in 152 patients ((a) 11qÀ, 17pÀ, trisomy 12; (b) 13qÀ). A total of 62 patients were concordant ZAP-70
À and 35 were concordant ZAP-70 þ CD38 þ ; 55 cases had discordant ZAP-70/CD38 phenotypes. Statistical analyses are based on w 2 tests.
ZAP-70 and CD38 expression in B-CLL R Schroers et al study by Crespo et al 12 and our own previous work. 15 Furthermore, we found that expression of the ZAP-70 protein was associated with other known adverse prognostic factors including disease stage at diagnosis, lactate dehydrogenase, b2-microglobulin, thymidine kinase and CD38 expression. Interestingly, we also observed a significantly higher incidence of autoimmune complications in ZAP-70-positive as compared to ZAP-70-negative patients, thus confirming data recently presented by Bosch et al (Blood 2004; 104(11): abstract).
As stability of ZAP-70 expression by the leukemic cell clone over time is an important precondition for the reliable use of this protein as a prognostic marker, we analyzed ZAP-70 levels in 38 patients from whom sequential samples were available. ZAP-70 expression levels were remarkably stable in the majority of patients; however, three out of 38 patients (7.9%) crossed the 20% threshold utilized to define ZAP-70 positivity. Notably, significant changes over time were observed in some patients with comparably high ZAP-70 protein levels, whereas minute variations were seen in patients with low intracellular staining for ZAP-70. This may be explained at least in part by technical limitations encountered in the currently used flow cytometry protocol, that is, the gating procedures used to define ZAP-70 positivity in T lymphocytes are inherently prone to small deviations in cursor positioning. Furthermore, ZAP-70 is homogenously expressed in B-CLL cells and therefore its quantification reflects a continuous shift in fluorescence intensity rather than demarcation of a separate ZAP-70 þ cell population. 15 Accordingly, random variations in ZAP-70 measurements are more likely to occur in B-CLL cells with relatively high ZAP-70 protein levels. These latter findings are in line with data by Bosch et al (Blood 2004; 104(11) : abstract), but appear to contrast those by Rassenti et al 14 showing a stable ZAP-70 expression over time in sequential samples from 10 individual patients. However, in one of these patients (10%), the 20% cutoff value was also crossed during the study period. Taken together, these data indicate a certain degree of variability in ZAP-70 expression over time, which, however, does not change the prognostic prediction made at diagnosis in the majority (492%) of cases. Clearly, further ZAP-70 time course analyses as well as standardization of flow cytometry protocols are needed to resolve this issue.
Next, we investigated the prognostic value of CD38 expression by the leukemic cell clone in our patient cohort. In accordance with our own previous work 20, 23 and that of others, 7, 17, 26, 27 CD38 expression was associated with a significantly shorter progression-free survival as compared to the CD38-negative patient subgroup. Expression of CD38 varied in a proportion of the here analyzed sequential B-CLL samples, although CD38 variations appeared to be smaller than those observed for ZAP-70. The overall prognostic prediction made at diagnosis changed in only one of 60 patients (1.7%) for whom samples were available for sequential analysis. Again, these findings are consistent with our own previous results 20 We then investigated in more detail the biological and molecular characteristics of the three subgroups defined by the combined determination of ZAP-70 and CD38. The phenomenon of discordant ZAP-70/CD38 expression was further explored by IgV H mutation analysis in this subset of patients. Interestingly, no association of unmutated IgV H genes with ZAP-70 expression was observed in the ZAP-70 þ CD38 À discordant patients. Conversely, we found a high proportion of IgV H unmutated genes (80%) in the CD38 þ ZAP-70 À subgroup. A possible explanation for these results would be falsely positive ZAP-70 protein measurements, which could be attributed at least in part to technical difficulties inherent in the flow cytometry assay. However, repeated ZAP-70 measurements in selected samples revealed constant results. Furthermore, both discordant subgroups comprised B-CLL samples with high-level expression of one marker but background levels of the other marker. Thus, the discordant findings could not solely be explained by expression levels close to the chosen cutoff values. Furthermore, cases with discordant IgV H /CD38 and also with discordant IgV H /ZAP-70 status have been previously described in independent studies by Hamblin et al, 17 Crespo et al 12 and Orchard et al. 13 These reports together with our current findings suggest that a subset of patients characterized by a discordant ZAP-70/CD38 status and a distinct clinical behavior is a real biological phenomenon rather than an artifact attributable to technical limitations of the flow cytometry assays employed. The hypothesis that the observed ZAP-70/CD38 subgroups represent distinct biological entities was further supported by our observation that both, discordant ZAP-70/CD38 and concordant ZAP-70 þ CD38 þ patients, exhibited a higher incidence of high-risk genomic aberrations such as 17p deletions and 11q deletions as compared to the ZAP-70 À / CD38 À patient cohort. To further investigate the molecular phenotype of the three clinical subgroups defined by combined determination of ZAP-70 and CD38, we compared their gene expression profiles in a subset of 35 patients, where gene expression data were available from a previously published microarray study. 23 Using multiclass supervised analysis, the expression of 37 genes was found to differ significantly between the three subgroups. Notably, the most pronounced gene expression differences were found for the comparison of concordant ZAP-70 þ CD38 þ vs ZAP-70 À CD38 À CLL samples, while cases with discordant ZAP-70/ CD38 expression usually exhibited intermediate signal intensities. Interestingly, six of these 37 differentially regulated genes, that is, interferon-induced protein 35 (IFI35), myxovirus resistance 1 (MX1), bone marrow stromal cell antigen 2 (BST2), signal transducer and activator of transcription 1 (STAT1), polymerase (RNA) II (DNA directed) polypeptide J (POLR2J) and CD38, are known interferon-stimulated genes 29 that were coordinately upregulated in the ZAP-70 þ CD38 þ samples. This finding in combination with data from the literature 30 showing that interferons secreted by dysregulated accessory T cells exert an antiapoptotic effect on CLL cells raises the possibility that interferon signaling may play a prominent role in the pathogenesis of ZAP-70 þ CD38 þ CLL cases. Furthermore, given that expression and aberrant phosphorylation of STAT1 has also been linked to apoptosis resistance in B-CLL cells, 31, 32 overexpression of this molecule may contribute to the more aggressive clinical behavior of ZAP-70 þ CD38 þ CLL cases. Another gene of potential functional importance found to be overexpressed in the ZAP-70 þ CD38 þ subgroup is transporter 1 (TAP1), which is a member of the superfamily of ATP binding cassette (ABC) transporter proteins. TAP1 has recently been shown to possess characteristics of a xenobiotic transporter molecule, which contributes to the atypical multidrug resistance phenotype of human cancer cells, 33, 34 and thus could also play a role in chemotherapy resistance in B-CLL cells.
In conclusion, our data show that the prognostic information given by ZAP-70 and CD38 expression is complementary. Combined analysis of these two markers allows for the separation of three B-CLL patient subgroups with good, intermediate and poor prognosis, and therefore could be used to guide treatment decisions especially in early clinical stages of the disease. Since flow cytometry can be used reliably to assess CLL samples for ZAP-70 and CD38, it should be more suitable for application in clinical laboratories than IgV H mutation analysis, which is a technically more demanding and expensive assay to perform. However, further studies are required to develop a standardized flow cytometry protocol that will allow comparison of ZAP-70 and CD38 measurements between different laboratories. Finally, the prognostic value of combined ZAP-70/CD38 analysis should be tested in the setting of a controlled prospective trial.
